Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02935309 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 |
| clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT05068193 | A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers | completed | Phase 1 | 57 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02354898 | A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 60 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02358395 | A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 12 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02906397 | Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT03259581 | Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin | completed | Phase 1 | 5 | University of MinnesotaOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT03884751 | Chimeric Antigen Receptor T Cells Targeting Glypican-3 | completed | Phase 1 | 9 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02248805 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | completed | Phase 1 | 95 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04811898 | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment(LNA-i-miR221) | completed | Phase 1 | 17 | Azienda Ospedaliera Universitaria Mater Domini, CatanzaroOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT02837029 | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT04191928 | Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy(PAP-UP) | completed | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03645148 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 7 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02507765 | Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT00892658 | Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04607291 | Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening | completed | Phase 1 | 183 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01126463 | 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas(LIP-RE-I) | completed | Phase 1 | 16 | Center Eugene MarquisOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03245190 | Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 27 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03300570 | Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2021 | clinicaltrials |
| NCT02292173 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02048384 | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | completed | Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT02953743 | Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 25 | Eisai Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02645864 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT02642913 | Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT04072679 | Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 50 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01666756 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT01183559 | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | completed | Phase 1 | 9 | Fox Chase Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2022source: clinicaltrials